{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:53:47Z","timestamp":1761512027286},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1994,9,1]],"date-time":"1994-09-01T00:00:00Z","timestamp":778377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1994,9,1]],"date-time":"1994-09-01T00:00:00Z","timestamp":778377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1994,9]]},"DOI":"10.1007\/bf00873961","type":"journal-article","created":{"date-parts":[[2004,12,24]],"date-time":"2004-12-24T19:40:26Z","timestamp":1103917226000},"page":"207-216","source":"Crossref","is-referenced-by-count":5,"title":["Pyrazine diazohydroxide (NSC-361456)"],"prefix":"10.1007","volume":"12","author":[{"given":"Madhav V.","family":"Dhodapkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Ames","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00873961_CR1","first-page":"297","volume":"2","author":"DC Baker","year":"1987","unstructured":"Baker DC, Hand ES, Plowman J, Safavy A, Haugwitz KD, Narayanan VL: Synthesis, chemical stability, and preclinical antitumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456). Anticancer Drug Des 2:297\u2013309, 1987","journal-title":"Anticancer Drug Des"},{"key":"BF00873961_CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0305-7372(90)90034-D","volume":"17","author":"H-H Fiebig","year":"1990","unstructured":"Fiebig H-H, Dietmar BP, Bernd WR, Plowman J:In vitro andin vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev 17:109\u2013117, 1990","journal-title":"Cancer Treat Rev"},{"key":"BF00873961_CR3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00264190","volume":"21","author":"DJ Moore","year":"1988","unstructured":"Moore DJ, Brodfuehrer JI, Wilke TJ, Powis G: Disposition and metabolism of the antitumor agent pyrazine 2 diazohydroxide in mouse and beagle dog. Cancer Chemother Pharmacol 21:269\u2013273, 1988","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00873961_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00170773","volume":"6","author":"JI Brodfuehrer","year":"1988","unstructured":"Brodfuehrer JI, Moore DJ, Melder DC, Wilke TJ, Powis G:In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation. Invest New Drugs 6:3\u20139, 1988","journal-title":"Invest New Drugs"},{"key":"BF00873961_CR5","first-page":"2032","volume":"29","author":"JT Liao","year":"1988","unstructured":"Liao JT, Merriman TN, Collins WT, Smith AC, Kastello MD, Grieshaber CK: Toxicological and pharmacokinetic evaluation of pyrazine diazohydroxide (NSC-361456). Proc Amer Assoc Cancer Res 29:2032, 1988","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"BF00873961_CR6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0378-4347(00)83443-X","volume":"388","author":"TJ Wilke","year":"1986","unstructured":"Wilke TJ, Kooistra KJ, Moore DJ, Powis G: Gas Chromatographie assay for the new antitumor agent pyrazine-2diazohydroxide (diazohydroxide) and its stability in buffer, blood and plasma. J Chromatogr 388:77\u201383, 1986","journal-title":"J Chromatogr"},{"key":"BF00873961_CR7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00175082","volume":"9","author":"D-L Du","year":"1991","unstructured":"Du D-L, Volpe DA, Grieshaber CK, Murphy MJ: Comparative toxicity of fotriecin, hepsulfam, and pyrazine diazohydroxide to human and murine hematopoietic system. Invest New Drugs 9:149\u2013157, 1991","journal-title":"Invest New Drugs"},{"key":"BF00873961_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF00686053","volume":"25","author":"SD Harrison","year":"1990","unstructured":"Harrison SD, Plowman J, Dykes D, Waud W, Griswold D: Schedule dependence, activity against natural metastases, and cross resistance of pyrazine diazohydroxide (sodium salt NSC 361456) in preclinical modelsin vivo. Cancer Chemother Pharm 25:425\u2013429, 1990","journal-title":"Cancer Chemother Pharm"},{"key":"BF00873961_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D: Pharmacokinetics. 2nd edition, Marcel Dekker, Inc., New York, NY, 1982, pp 409\u2013416","edition":"2nd edition"},{"key":"BF00873961_CR10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-5193(68)90188-4","volume":"20","author":"JG Wagner","year":"1968","unstructured":"Wagner JG: Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theoret Biol 20:173\u2013201, 1968","journal-title":"J Theoret Biol"},{"key":"BF00873961_CR11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokin Biopharm 9:503\u2013512, 1981","journal-title":"J Pharmacokin Biopharm"},{"key":"BF00873961_CR12","first-page":"4843","volume":"53","author":"JG Supko","year":"1993","unstructured":"Supko JG, Balcerzak SP, Kraut EH: Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Cancer Res 53:4843\u20134849, 1993","journal-title":"Cancer Res"},{"key":"BF00873961_CR13","first-page":"3182","volume":"33","author":"NJ Vogelzang","year":"1992","unstructured":"Vogelzang NJ, Janisch L, Berezin F, Mick R, Schilsky R, Walter P, Ratain MJ: Pyrazine diazohydroxide (PZDH): A phase I trial. Proc Amer Assoc Cancer Res 33:3182, 1992","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"BF00873961_CR14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","volume":"10","author":"EK Rowinsky","year":"1992","unstructured":"Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, Mc Guire WP, Sartorius SE, Lubjeko BG, Kaufman SH, Donehower RC: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10:647\u2013656, 1992","journal-title":"J Clin Oncol"},{"key":"BF00873961_CR15","first-page":"1513","volume":"46","author":"MJ Egorin","year":"1986","unstructured":"Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Engish KL, Aisner J: Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res 46:1513\u20131520, 1986","journal-title":"Cancer Res"},{"key":"BF00873961_CR16","first-page":"617","volume":"47","author":"MJ Egorin","year":"1987","unstructured":"Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J: Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five day continuous infusion. Cancer Res 47:617\u2013623, 1987","journal-title":"Cancer Res"},{"key":"BF00873961_CR17","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1200\/JCO.1990.8.10.1739","volume":"8","author":"MJ Ratain","year":"1990","unstructured":"Ratain MJ, Schilsky RL, Conley BA, Egorin MJ: Pharma codynamics in cancer therapy. J Clin Oncol 8:1739\u20131753, 1990","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00873961\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00873961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T03:49:09Z","timestamp":1678506549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00873961"}},"subtitle":["Phase I clinical and pharmacokinetic studies"],"short-title":[],"issued":{"date-parts":[[1994,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,9]]}},"alternative-id":["BF00873961"],"URL":"https:\/\/doi.org\/10.1007\/bf00873961","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,9]]}}}